Comprehensive histologic scoring to maximize the predictability of pathology-generated equation of breast cancer oncotype dx recurrence score

Applied Immunohistochemistry and Molecular Morphology

Volumn 24, Issue 10, 2016, Pages 703-711

  Khoury, Thaer ^a   Huang, Xiao ^a   Chen, Xiwei ^b   Wang, Dan ^b   Liu, Song ^b   Opyrchal, Mateusz ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b Biostatistics and Bioinformatics   (United States)

Author keywords

Breast cancer; Histomorphology; Oncotype recurrence score

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER GRADING; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MIDDLE AGED; MITOSIS RATE; ONCOTYPE DX RECURRENCE SCORE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; TISSUE SECTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR NECROSIS; TUMOR VOLUME; BREAST TUMOR; CLASSIFICATION; IMMUNOHISTOCHEMISTRY; METABOLISM; PATHOLOGY; TUMOR RECURRENCE;

BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM RECURRENCE, LOCAL; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84955592160     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0000000000000248     Document Type: Article

References (25)

1. Pereira H, Pinder SE, Sibbering DM, et al. Pathological prognostic factors in breast cancer. IV: should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma. Histopathology. 1995;27:219-226.
2. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403-410.
3. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817-2826.
4. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptorpositive breast cancer. J Clin Oncol. 2006;24:3726-3734.
5. Habel LA, Shak S, Jacobs MK, et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res. 2006;8: R25.
6. Esteva FJ, Sahin AA, Cristofanilli M, et al. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with nodenegative breast cancer not receiving adjuvant systemic therapy. Clin Cancer Res. 2005;11:3315-3319.
7. Gianni L, Zambetti M, Clark K, et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol. 2005;23:7265-7277.
8. Toi M, Iwata H, Yamanaka T, et al. Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population. Cancer. 2010;116:3112-3118.
9. Flanagan MB, Dabbs DJ, Brufsky AM, et al. Histopathologic variables predict Oncotype DX recurrence score. Mod Pathol. 2008;21:1255-1261.
10. Klein ME, Dabbs DJ, Shuai Y, et al. Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis. Mod Pathol. 2013;26: 658-664.
11. Acs G, Esposito NN, Kiluk J, et al. A mitotically active, cellular tumor stroma and/or inflammatory cells associated with tumor cells may contribute to intermediate or high Oncotype DX Recurrence Scores in low-grade invasive breast carcinomas. Mod Pathol. 2012;25:556-566.
12. Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17:1474-1481.
13. Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. J Clin Oncol. 2013;32:1-18.
14. Khoury T, Yan L, Liu S, et al. sRT-qPCR assay for ER and PR correlation with IHC: a study of three different clones. Appl Immunohistochem Mol Morphol. 2015;23:178-187.
15. Dabbs DJ, Klein ME, Mohsin SK, et al. High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study. J Clin Oncol. 2011;29,4279-4285.
16. Fireson HF Jr, Wolber RA, Berean KW, et al. Interobserver reproducibility of the Nottingham modification of the Bloom and Richardson histologic grading scheme for infiltrating ductal carcinoma. Am J Clin Pathol. 1995;103:195-198.
17. Carlson JJ, Roth JA. The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis. Breast Cancer Res Treat. 2013;141:13-22.
18. Weigelt B, Baehner FL, Reis-Filho JS. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol. 2010;220:263-280.
19. Baehner F, Quale C, Pomeroy C, et al. Biopsy cavities in breast cancer specimens: their impact on quantitative RT-PCR gene expression profiles and recurrence risk assessment (abstract). Mod Pathol. 2008;22:28A-29A.
20. Diab SG, Clark GM, Osborne CK, et al. Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. J Clin Oncol. 1999;17:1442-1448.
21. Gooden MJ, de Bock GH, Leffers N, et al. The prognostic influence of tumor infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011;105:93-103.
22. Brown SD, Warren RL, Gibb EA, et al. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res. 2014;24:743-750.
23. Salgado R, Denkert C, Demaria S, et al. The evaluation of tumorinfiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26: 259-271.
24. Gilchrist KW, Gray R, Fowble B, et al. Tumor necrosis is a prognostic predictor for early recurrence and death in lymph nodepositive breast cancer: a 10-year follow-up study of 728 Eastern Cooperative Oncology Group patients. J Clin Oncol. 1993;11: 1929-1935.
25. Allison KH, Kandalaft PL, Sitlani CM, et al. Routine pathologic parameters can predict Oncotype DX recurrence scores in subsets of ER positive patients: who does not always need testing? Breast Cancer Res Treat. 2012;131:413-424.